In this episode, Sacha sits down with Stephanie Wang, the founder of KA! Empathogenics. They get into the exciting benefits Kanna, sometimes dubbed as 'Nature's MDMA'.
Similar Posts
Doug Drysdale On How CYB-003 Is Better Than Psilocybin
In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion)
MindMed (Nasdaq:MNMD, NEO:MMED) has launched recruitment for their phase 2a clinical trial, testing using LSD microdoses to treat Adult ADHD!
MindMed’s stock has been down a lot recently, which has people asking “should I sell MindMed”, or “Is MindMed stock a good investment?”, or “why is MindMed stock down?”.
A lot of this drop has to do with a lack of news, not bad news. Now, at long last we finally have some good news! I have been looking forward to this trial starting for over a year now!
This LSD microdosing study is part of Project Flow, MindMed’s LSD microdosing division.
Microdosing LSD, anecdotally, has been shown to: increase focus; decrease anxiety; increase creativity; and improve mood. As improving focus and decreasing anxiety are two issues individuals with ADHD often need help with, it is possible that this may be a better medication than stimulants like Adderall.
The 52 person, placebo controlled study will give 20 micrograms of LSD to Adult ADHD sufferers twice a week for 6 weeks. Six weeks after treatment, the patients symptoms will be compared to where they were before the trial, and compared against the placebo group.
If they do show significant improvement, it will be the first scientific evidence that LSD microdoses can help treat adult ADHD.
Not only would this help tens of millions of people, it would also be lucrative for MindMed, as in the USA alone, the ADHD treatment market is valued at $12.9 billion annually.
Is LSD microdosing good for you? Can LSD Microdosing improve your mental health and Creativity? MindMed aims to find out!
References:
Press Release
https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html
MindMed Investor’s Deck
https://mindmed.co/wp-content/uploads/2021/12/MindMed-Presentation-December-2021.pdf
New CEO
https://www.newswire.ca/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-879570624.html
Microdosing study 1
https://pubmed.ncbi.nlm.nih.gov/34795334/
Microdosing study 2
https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Microdosing #ADHD
Psychedelic Spotlight Interview with Douglas K. Gordon
Psychedelic Spotlight Interview with Douglas K. Gordon In this episode…
Interview With Henri Sant-Cassia, The Conscious Fund
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founding Partner at The Conscious Fund, Henri Sant-Cassia.
Rick Doblin Interview: Psychedelics and the Soviets, A “Driver’s License” to take Drugs, Curing PTSD
Donate to MAPS: https://maps.org/about-maps/our-team/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.
Can MDMA treat PTSD? Rick Doblin (and the science) says YES!
Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!
Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!
To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.
Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/
CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/
Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495
#RickDoblin #MDMA #PSYCHEDELICS